Latest Global Expansion News

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

WhiteHawk has locked in A$685,000 from customer renewals and program expansions, reinforcing its foothold in cybersecurity across financial services, education, and government sectors.

WhiteHawk Limited has appointed Adrian Vallino as Group CEO to spearhead its global expansion and commercialisation of the Quixxi Clarity AI platform, aiming to grow recurring revenue and diversify its distribution channels.

Truscreen Group has issued nearly 150 million new shares at NZ$0.013 each, expanding its share base by 17.4% following a renounceable rights issue. The fully paid shares rank equally with existing stock, lifting total ordinary shares to just over one billion.

Cooks Coffee lifted UK and Ireland store sales 22.8% to NZ$95.8 million in FY26, with EBITDA up 14% to NZ$1.39 million. Despite operational growth and debt reduction, net liabilities and liquidity pressures raise material going concern doubts.

TruScreen Group has completed a substantially oversubscribed NZ$2.9 million rights issue, boosting total capital raised to over NZ$4 million. The funds are set to support the company’s global expansion in cervical screening technology.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Schoolblazer Group has consolidated its fragmented debt into a $110 million multi-currency facility with Westpac, providing significant headroom for growth and lowering its cost of debt.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AoFrio Limited has successfully closed a renounceable pro-rata rights issue, securing NZ$4.428 million to fund its push into US and European markets and advance AI-driven innovations in cold drink equipment.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.